Search Results - "Voss, M.H."

2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC) by McDermott, D.F, Infante, J.R, Chowdhury, S, Voss, M.H, Motzer, R.J, Perini, R.F, Morosky, A, Zheng, F.F, White, B.C, Wang, Q, Jewell, R.C, Rini, B.I

Get full text

717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC) by Rini, B.I., Plimack, E.R., Powles, T.B., Voss, M.H., Gurney, H.P., Silverman, R., Perini, R., Rodriguez-Lopez, K., Choueiri, T.K.

Get full text

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors by Shah, A.Y., Kotecha, R.R., Lemke, E.A., Chandramohan, A., Chaim, J.L., Msaouel, P., Xiao, L., Gao, J., Campbell, M.T., Zurita, A.J., Wang, J., Corn, P.G., Jonasch, E., Motzer, R.J., Sharma, P., Voss, M.H., Tannir, N.M.

“…Immune checkpoint inhibitors (ICIs) are being increasingly utilised in the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC)…”
Get full text

1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy by Shah, N.J., Campbell, M.T., Mao, S., Ornstein, M.C., Haas, N.B., Gao, X., Hammers, H., Keshava-Prasad, H., Hoimes, C.J., Hussain, A., George, S., Gourdin, T.S., Nelson, A., Yan, H., Esquibel, V., McIntyre, G., Geller, R., Voss, M.H., Rini, B.I., Beckermann, K.

Get full text

Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC) by Voss, M.H., Azad, A.A., Hansen, A.R., Gray, J.E., Welsh, S.J., Achour, I., Hu, H., Lewis, L., Walcott, F.L., Oosting, S.F.

Get full text

1269P - Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC) by Voss, M.H., Azad, A.A., Hansen, A.R., Gray, J.E., Welsh, S.J., Achour, I., Hu, H., Lewis, L., Walcott, F.L., Oosting, S.F.

“…MEDI0680 is a humanised IgG4κ anti-programmed cell death-1 (PD-1) mAb. We hypothesised that simultaneous blockade of PD-1:PD-L1/PD-L2 with MEDI0680 (M) and…”
Get full text

1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) by Voss, M.H., Garmezy, B., Kim, S.H., Maroto Rey, J.P., Mansinho, A.B., Rodriguez-Vida, A., Oliveira, J., van Dongen, M., Rodríguez, L. Medina, Negrier, S., Tran, B., Carneiro, B.A., Alvarez, E. Castanon, Rha, S.Y., Wang, Y., Gainer, S.D., Tang, Z., Achour, I., Asare, J.M., Albiges, L.

Get full text

Deciphering radiological stable disease to immune checkpoint inhibitors by Luo, J., Wu, S., Rizvi, H., Zhang, Q., Egger, J.V., Osorio, J.C., Schoenfeld, A.J., Plodkowski, A.J., Ginsberg, M.S., Callahan, M.K., Maher, C., Shoushtari, A.N., Postow, M.A., Voss, M.H., Kotecha, R.R., Gupta, A., Raja, R., Kris, M.G., Hellmann, M.D.

“…‘Stable disease (SD)’ as per RECIST is a common but ambiguous outcome in patients receiving immune checkpoint inhibitors (ICIs). This study aimed to…”
Get full text

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma by Voss, M.H., Hussain, A., Vogelzang, N., Lee, J.L., Keam, B., Rha, S.Y., Vaishampayan, U., Harris, W.B., Richey, S., Randall, J.M., Shaffer, D., Cohn, A., Crowell, T., Li, J., Senderowicz, A., Stone, E., Figlin, R., Motzer, R.J., Haas, N.B., Hutson, T.

“…Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity…”
Get full text

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma by Nadal, R., Amin, A., Geynisman, D.M., Voss, M.H., Weinstock, M., Doyle, J., Zhang, Z., Viudez, A., Plimack, E.R., McDermott, D.F., Motzer, R., Rini, B., Hammers, H.J.

“…Emerging agents blocking the programmed cell death 1 (PD-1) pathway show activity in metastatic clear cell renal cell carcinoma (mRCC). The aim of this study…”
Get full text

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies by Barrios, D.M., Phillips, G.S., Geisler, A.N., Trelles, S.R., Markova, A., Noor, S.J., Quigley, E.A., Haliasos, H.C., Moy, A.P., Schram, A.M., Bromberg, J., Funt, S.A., Voss, M.H., Drilon, A., Hellmann, M.D., Comen, E.A., Narala, S., Patel, A.B., Wetzel, M., Jung, J.Y., Leung, D.Y.M., Lacouture, M.E.

“…Immunoglobulin E (IgE) blockade with omalizumab has demonstrated clinical benefit in pruritus-associated dermatoses (e.g. atopic dermatitis, bullous…”
Get full text

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies by Voss, M.H., Bastos, D.A., Karlo, C.A., Ajeti, A., Hakimi, A.A., Feldman, D.R., Hsieh, J.J., Molina, A.M., Patil, S., Motzer, R.J.

“…The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma (RCC) were primarily conducted in…”
Get full text

Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN+PEMBRO) or sunitinib (SUN) in the CLEAR study by Voss, M.H., Powles, T., Mcgregor, B., Porta, C., Grünwald, V., Merchan, J.R., Rolland, F., Maroto-Rey, P., Goh, J.C., Xing, D., Perini, R.F., Mckenzie, J., Mody, K., Motzer, R.J.

Get full text

Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma by Lee, C.-H., Motzer, R.J., Glen, H., Michaelson, M.D., Larkin, J., Minoshima, Y., Kanekiyo, M., Dairiki, R., Sachdev, P., Dutcus, C.E., Funahashi, Y., Voss, M.H.

Get full text

Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study by Hammers, H., Plimack, E.R., Infante, J.R., Rini, B.I., McDermott, D., Lewis, L., Voss, M.H., Sharma, P., Pal, S.K., Razak, A., Kollmannsberger, C.K., Heng, D., Spratlin, J., McHenry, B., Gagnier, P., Amin, A.

Get full text

Total Donor Chimerism in the Day 21 Bone Marrow Predicts Sustained Donor Neutrophil Engraftment Following Double Unit Cord Blood Transplantation (CBT) by Avery, S, Voss, M.H, Gonzales, A.M, Lubin, M, Castro-Malaspina, H, Kernan, N.A, Scaradavou, A, Hedvat, C, Stevens, C.E, Barker, J.N

Get full text

Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma by Carlo, M.I., Manley, B., Patil, S., Woo, K.M., Coskey, D.T., Redzematovic, A., Arcila, M., Ladanyi, M., Lee, W., Chen, Y.B., Lee, C.H., Feldman, D.R., Hakimi, A.A., Motzer, R.J., Hsieh, J.J., Voss, M.H.

“…Background: Mutations in VHL, PBRM1, SETD2, BAP1, and KDM5C are common in clear cell renal cell carcinoma (ccRCC), and presence of certain mutations has been…”
Get full text

Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation by Avery, S, Voss, M H, Gonzales, A M, Lubin, M, Castro-Malaspina, H, Giralt, S, Kernan, N A, Scaradavou, A, Hedvat, C V, Stevens, C E, Barker, J N

“…Delayed or failed engraftment remains a concern after cord blood transplantation (CBT) even when using double-unit grafts. Therefore, we analyzed the…”
Get full text